toujeo logo

Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

Toujeo® is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. Discover the Toujeo® Evidence in T1DM below and get access to patient supporting tools and materials for children with T1DM who have been prescribed Toujeo®.

Randomised, Open Label Clinical Trial

Toujeo vs Insulin Glargine 100 U/mL

6 month, randomised, open label, double-arm, parallel group, non-inferiority study in 463 patients with T1DM.

Objective: To demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL (a standard of care) in change of HbA1c from baseline to Week 26 in children/adolescents aged >6 years with T1DM.

Meta Analysis

Toujeo® vs Insulin Glargine 100 U/mL

Post-hoc meta-analysis of three EDITION 6-month, Phase III, randomised clinical trials in a broad population including children aged 6+.

Post-hoc meta-analysis aim:Exploring the risk for severe hypoglycaemia with Toujeo® vs insulin glargine 100 units/mL in the pool of studied patients with T1DM.

Edition 4 (549 adults), Edition Junior (463 children), Edition JP (245 adults).


Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

MAT-XU-2205636 (v4.0)
Date of Preparation: September 2023